| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medical Records Systems, Computerized | 48 | 2020 | 1190 | 4.390 |
Why?
|
| Electronic Health Records | 77 | 2024 | 4760 | 4.290 |
Why?
|
| Computational Biology | 44 | 2021 | 3501 | 3.680 |
Why?
|
| Genomics | 48 | 2024 | 5788 | 3.190 |
Why?
|
| Rare Diseases | 20 | 2024 | 618 | 3.110 |
Why?
|
| Information Storage and Retrieval | 30 | 2019 | 820 | 3.030 |
Why?
|
| Autistic Disorder | 14 | 2024 | 1216 | 2.580 |
Why?
|
| Software | 49 | 2021 | 4416 | 2.460 |
Why?
|
| Gene Expression Profiling | 62 | 2020 | 9404 | 2.350 |
Why?
|
| Medical Informatics | 19 | 2021 | 732 | 2.290 |
Why?
|
| Databases, Genetic | 29 | 2020 | 1737 | 2.270 |
Why?
|
| Phenotype | 68 | 2024 | 16533 | 1.990 |
Why?
|
| Computer Communication Networks | 21 | 2020 | 294 | 1.960 |
Why?
|
| Genome, Human | 30 | 2024 | 4414 | 1.840 |
Why?
|
| Algorithms | 58 | 2022 | 13952 | 1.580 |
Why?
|
| Confidentiality | 21 | 2019 | 609 | 1.580 |
Why?
|
| Artificial Intelligence | 20 | 2024 | 2547 | 1.570 |
Why?
|
| Developmental Disabilities | 11 | 2023 | 1504 | 1.560 |
Why?
|
| Microcephaly | 5 | 2023 | 425 | 1.550 |
Why?
|
| Natural Language Processing | 21 | 2020 | 1135 | 1.530 |
Why?
|
| Information Dissemination | 15 | 2024 | 1128 | 1.520 |
Why?
|
| Medical Record Linkage | 12 | 2021 | 286 | 1.520 |
Why?
|
| Systems Integration | 15 | 2017 | 426 | 1.440 |
Why?
|
| Computer Security | 18 | 2022 | 260 | 1.430 |
Why?
|
| Nervous System Malformations | 3 | 2022 | 244 | 1.430 |
Why?
|
| Humans | 495 | 2024 | 757650 | 1.380 |
Why?
|
| Child Development Disorders, Pervasive | 6 | 2013 | 600 | 1.340 |
Why?
|
| User-Computer Interface | 23 | 2020 | 1397 | 1.270 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 38 | 2012 | 3774 | 1.240 |
Why?
|
| Epilepsy | 8 | 2024 | 3270 | 1.140 |
Why?
|
| Biomedical Research | 13 | 2021 | 3416 | 1.130 |
Why?
|
| Genetic Variation | 21 | 2020 | 6549 | 1.120 |
Why?
|
| Delivery of Health Care | 12 | 2024 | 5325 | 1.110 |
Why?
|
| Sequence Analysis, DNA | 20 | 2021 | 4710 | 1.080 |
Why?
|
| Database Management Systems | 8 | 2010 | 257 | 1.080 |
Why?
|
| Inflammatory Bowel Diseases | 14 | 2019 | 2417 | 1.000 |
Why?
|
| Depressive Disorder, Major | 20 | 2021 | 4744 | 0.990 |
Why?
|
| Genetic Testing | 17 | 2024 | 3529 | 0.990 |
Why?
|
| Colitis, Ulcerative | 10 | 2023 | 1919 | 0.960 |
Why?
|
| Data Collection | 8 | 2021 | 3320 | 0.960 |
Why?
|
| Internet | 25 | 2015 | 3081 | 0.950 |
Why?
|
| Genes | 6 | 2019 | 1844 | 0.940 |
Why?
|
| Medical Informatics Applications | 6 | 2011 | 178 | 0.930 |
Why?
|
| Genetic Predisposition to Disease | 33 | 2024 | 17767 | 0.930 |
Why?
|
| Hospital Information Systems | 14 | 2009 | 393 | 0.910 |
Why?
|
| Polymorphism, Single Nucleotide | 28 | 2023 | 15773 | 0.900 |
Why?
|
| Incidental Findings | 5 | 2014 | 693 | 0.900 |
Why?
|
| Child | 81 | 2024 | 79787 | 0.870 |
Why?
|
| Patient Access to Records | 4 | 2016 | 119 | 0.850 |
Why?
|
| Crohn Disease | 9 | 2019 | 2275 | 0.840 |
Why?
|
| Gene Expression Regulation | 32 | 2019 | 11893 | 0.840 |
Why?
|
| Golgi Apparatus | 1 | 2024 | 404 | 0.820 |
Why?
|
| Data Mining | 9 | 2021 | 551 | 0.820 |
Why?
|
| Molecular Diagnostic Techniques | 5 | 2020 | 610 | 0.810 |
Why?
|
| Hereditary Autoinflammatory Diseases | 1 | 2022 | 42 | 0.790 |
Why?
|
| Patients | 4 | 2023 | 902 | 0.790 |
Why?
|
| Genome-Wide Association Study | 28 | 2023 | 12604 | 0.790 |
Why?
|
| Nervous System Diseases | 5 | 2023 | 1647 | 0.780 |
Why?
|
| Software Design | 4 | 2012 | 171 | 0.780 |
Why?
|
| Mutation | 26 | 2024 | 29928 | 0.770 |
Why?
|
| Electron Transport Complex III | 1 | 2021 | 31 | 0.760 |
Why?
|
| Electron Transport Complex II | 1 | 2021 | 53 | 0.760 |
Why?
|
| Decision Making, Computer-Assisted | 2 | 2019 | 146 | 0.740 |
Why?
|
| National Library of Medicine (U.S.) | 2 | 2019 | 34 | 0.740 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2020 | 33 | 0.720 |
Why?
|
| Medicine | 3 | 2023 | 940 | 0.720 |
Why?
|
| Access to Information | 2 | 2022 | 316 | 0.710 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 2 | 2020 | 253 | 0.700 |
Why?
|
| Clinical Laboratory Techniques | 6 | 2018 | 747 | 0.690 |
Why?
|
| Cerebellar Ataxia | 1 | 2021 | 149 | 0.680 |
Why?
|
| Neuromuscular Diseases | 2 | 2019 | 255 | 0.670 |
Why?
|
| Spasms, Infantile | 4 | 2021 | 296 | 0.670 |
Why?
|
| Genetic Association Studies | 8 | 2021 | 2717 | 0.660 |
Why?
|
| Male | 155 | 2024 | 358227 | 0.650 |
Why?
|
| Coloboma | 1 | 2019 | 59 | 0.650 |
Why?
|
| Gene Expression Regulation, Developmental | 6 | 2020 | 3602 | 0.650 |
Why?
|
| Platinum | 1 | 2020 | 219 | 0.650 |
Why?
|
| Parents | 11 | 2023 | 3548 | 0.640 |
Why?
|
| Cerebellum | 7 | 2019 | 1497 | 0.640 |
Why?
|
| Female | 169 | 2024 | 389985 | 0.640 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2021 | 285 | 0.640 |
Why?
|
| False Positive Reactions | 7 | 2016 | 956 | 0.640 |
Why?
|
| Genome | 10 | 2021 | 1739 | 0.640 |
Why?
|
| Clinical Laboratory Information Systems | 4 | 2012 | 108 | 0.640 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2019 | 87 | 0.640 |
Why?
|
| Papilledema | 1 | 2020 | 130 | 0.630 |
Why?
|
| Arthrogryposis | 1 | 2019 | 68 | 0.620 |
Why?
|
| Zebrafish | 6 | 2024 | 2992 | 0.620 |
Why?
|
| Fraud | 1 | 2019 | 66 | 0.620 |
Why?
|
| Models, Genetic | 20 | 2020 | 3441 | 0.610 |
Why?
|
| Pharmacogenetics | 3 | 2014 | 675 | 0.610 |
Why?
|
| Caenorhabditis elegans Proteins | 2 | 2020 | 866 | 0.600 |
Why?
|
| Siblings | 4 | 2024 | 824 | 0.600 |
Why?
|
| Reproducibility of Results | 39 | 2023 | 20039 | 0.600 |
Why?
|
| Gene Expression | 15 | 2017 | 7584 | 0.600 |
Why?
|
| Information Systems | 6 | 2021 | 397 | 0.590 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2024 | 568 | 0.590 |
Why?
|
| Databases, Factual | 21 | 2021 | 7926 | 0.580 |
Why?
|
| Genotype | 16 | 2021 | 12951 | 0.580 |
Why?
|
| Comorbidity | 13 | 2022 | 10478 | 0.570 |
Why?
|
| Mitochondrial Diseases | 1 | 2021 | 340 | 0.570 |
Why?
|
| Databases as Topic | 5 | 2002 | 472 | 0.570 |
Why?
|
| Epistasis, Genetic | 1 | 2019 | 350 | 0.560 |
Why?
|
| Child, Preschool | 45 | 2024 | 42044 | 0.560 |
Why?
|
| United States | 61 | 2024 | 71907 | 0.560 |
Why?
|
| Computer Systems | 15 | 2011 | 470 | 0.550 |
Why?
|
| Decision Support Systems, Clinical | 4 | 2022 | 1160 | 0.550 |
Why?
|
| Bayes Theorem | 9 | 2019 | 2320 | 0.540 |
Why?
|
| Multifactorial Inheritance | 9 | 2023 | 1365 | 0.540 |
Why?
|
| MicroRNAs | 6 | 2022 | 3782 | 0.540 |
Why?
|
| NF-kappa B | 2 | 2022 | 2472 | 0.530 |
Why?
|
| Medical Records | 7 | 2017 | 1406 | 0.530 |
Why?
|
| Adolescent | 53 | 2024 | 87832 | 0.530 |
Why?
|
| Adult | 97 | 2024 | 219747 | 0.520 |
Why?
|
| Patient Selection | 4 | 2021 | 4235 | 0.520 |
Why?
|
| Caenorhabditis elegans | 3 | 2023 | 1443 | 0.520 |
Why?
|
| Research Design | 7 | 2021 | 6151 | 0.510 |
Why?
|
| Programming Languages | 8 | 2017 | 128 | 0.510 |
Why?
|
| Toxicogenetics | 2 | 2016 | 20 | 0.510 |
Why?
|
| Translating | 1 | 2016 | 143 | 0.510 |
Why?
|
| Lung Neoplasms | 9 | 2020 | 13267 | 0.500 |
Why?
|
| Insurance Claim Review | 2 | 2021 | 735 | 0.500 |
Why?
|
| Body Dysmorphic Disorders | 1 | 2019 | 243 | 0.500 |
Why?
|
| Opioid-Related Disorders | 2 | 2022 | 2141 | 0.500 |
Why?
|
| Protein Kinases | 1 | 2022 | 1610 | 0.500 |
Why?
|
| Autoimmune Diseases | 5 | 2024 | 2243 | 0.490 |
Why?
|
| Genetics, Medical | 5 | 2013 | 336 | 0.490 |
Why?
|
| Dyslipidemias | 2 | 2020 | 867 | 0.490 |
Why?
|
| Evidence-Based Medicine | 4 | 2019 | 3667 | 0.490 |
Why?
|
| Cohort Studies | 42 | 2023 | 41198 | 0.480 |
Why?
|
| Haploinsufficiency | 3 | 2024 | 327 | 0.480 |
Why?
|
| Seizures | 4 | 2024 | 2919 | 0.480 |
Why?
|
| Eye Diseases | 1 | 2020 | 651 | 0.470 |
Why?
|
| Genetics, Population | 3 | 2009 | 929 | 0.470 |
Why?
|
| Benchmarking | 1 | 2021 | 1042 | 0.460 |
Why?
|
| Forecasting | 6 | 2021 | 2919 | 0.460 |
Why?
|
| Gene Expression Regulation, Neoplastic | 11 | 2018 | 8505 | 0.460 |
Why?
|
| Penetrance | 1 | 2016 | 388 | 0.460 |
Why?
|
| ROC Curve | 16 | 2023 | 3562 | 0.460 |
Why?
|
| Databases, Nucleic Acid | 7 | 2005 | 204 | 0.460 |
Why?
|
| Metabolomics | 3 | 2021 | 1629 | 0.460 |
Why?
|
| Analgesics, Opioid | 2 | 2022 | 3762 | 0.460 |
Why?
|
| Syndrome | 10 | 2023 | 3261 | 0.450 |
Why?
|
| International Classification of Diseases | 8 | 2019 | 891 | 0.440 |
Why?
|
| Clinical Trials as Topic | 5 | 2021 | 7982 | 0.440 |
Why?
|
| Cluster Analysis | 19 | 2019 | 2696 | 0.440 |
Why?
|
| Family | 5 | 2024 | 3188 | 0.430 |
Why?
|
| Transcription Factors | 15 | 2023 | 12092 | 0.420 |
Why?
|
| Genetic Counseling | 4 | 2021 | 624 | 0.420 |
Why?
|
| Young Adult | 34 | 2024 | 58764 | 0.420 |
Why?
|
| Arthritis, Rheumatoid | 12 | 2020 | 3753 | 0.420 |
Why?
|
| Computing Methodologies | 1 | 2012 | 17 | 0.410 |
Why?
|
| Group VI Phospholipases A2 | 1 | 2022 | 16 | 0.410 |
Why?
|
| Lamin Type B | 1 | 2022 | 26 | 0.400 |
Why?
|
| Neuroaxonal Dystrophies | 1 | 2022 | 26 | 0.400 |
Why?
|
| Animals | 65 | 2024 | 167777 | 0.400 |
Why?
|
| Informatics | 1 | 2012 | 73 | 0.390 |
Why?
|
| Genetic Diseases, Inborn | 4 | 2019 | 601 | 0.390 |
Why?
|
| Genetic Research | 3 | 2014 | 171 | 0.390 |
Why?
|
| Case-Control Studies | 25 | 2024 | 22024 | 0.390 |
Why?
|
| Marfan Syndrome | 1 | 2024 | 236 | 0.390 |
Why?
|
| Infant | 29 | 2022 | 36043 | 0.390 |
Why?
|
| Gastrointestinal Agents | 2 | 2016 | 508 | 0.390 |
Why?
|
| Infant, Newborn | 29 | 2022 | 26173 | 0.390 |
Why?
|
| Models, Organizational | 1 | 2015 | 546 | 0.390 |
Why?
|
| Health Insurance Portability and Accountability Act | 3 | 2020 | 105 | 0.390 |
Why?
|
| Computer Simulation | 15 | 2023 | 6198 | 0.380 |
Why?
|
| Alleles | 14 | 2024 | 6894 | 0.380 |
Why?
|
| Medical History Taking | 5 | 2017 | 772 | 0.380 |
Why?
|
| Microsatellite Repeats | 1 | 2024 | 785 | 0.380 |
Why?
|
| Colon | 1 | 2019 | 1788 | 0.380 |
Why?
|
| Health Records, Personal | 3 | 2022 | 127 | 0.380 |
Why?
|
| Physician-Patient Relations | 5 | 2017 | 3239 | 0.380 |
Why?
|
| Muscular Diseases | 2 | 2024 | 551 | 0.380 |
Why?
|
| Bipolar Disorder | 7 | 2021 | 5083 | 0.380 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2024 | 829 | 0.380 |
Why?
|
| Monitoring, Physiologic | 10 | 2022 | 1780 | 0.380 |
Why?
|
| Peer Review, Research | 3 | 2021 | 340 | 0.370 |
Why?
|
| Calcium Channels, L-Type | 2 | 2024 | 240 | 0.370 |
Why?
|
| Middle Aged | 76 | 2024 | 219219 | 0.370 |
Why?
|
| Sequence Homology | 2 | 2019 | 195 | 0.370 |
Why?
|
| Angelman Syndrome | 1 | 2023 | 140 | 0.370 |
Why?
|
| Patient Identification Systems | 4 | 2007 | 75 | 0.370 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2012 | 2824 | 0.370 |
Why?
|
| Connective Tissue Diseases | 1 | 2024 | 285 | 0.360 |
Why?
|
| Telemedicine | 3 | 2023 | 3016 | 0.360 |
Why?
|
| Conserved Sequence | 3 | 2005 | 1164 | 0.360 |
Why?
|
| Toll-Like Receptors | 1 | 2024 | 590 | 0.360 |
Why?
|
| Telomere | 1 | 2017 | 931 | 0.360 |
Why?
|
| S Phase | 2 | 2011 | 422 | 0.360 |
Why?
|
| Data Interpretation, Statistical | 7 | 2019 | 2687 | 0.360 |
Why?
|
| Tuberous Sclerosis | 1 | 2018 | 1030 | 0.360 |
Why?
|
| Pandemics | 10 | 2024 | 8601 | 0.360 |
Why?
|
| Genetic Privacy | 2 | 2009 | 59 | 0.360 |
Why?
|
| Toxicity Tests | 1 | 2010 | 112 | 0.360 |
Why?
|
| Teratogens | 1 | 2010 | 117 | 0.350 |
Why?
|
| Trinucleotide Repeat Expansion | 4 | 2014 | 247 | 0.350 |
Why?
|
| Expert Systems | 3 | 1996 | 79 | 0.350 |
Why?
|
| Vaccination | 1 | 2022 | 3356 | 0.350 |
Why?
|
| DNA Copy Number Variations | 3 | 2014 | 2012 | 0.340 |
Why?
|
| Public Health | 2 | 2022 | 2658 | 0.340 |
Why?
|
| Autoimmunity | 3 | 2024 | 1358 | 0.340 |
Why?
|
| Proteome | 2 | 2018 | 1855 | 0.340 |
Why?
|
| Hospital Shared Services | 1 | 2009 | 16 | 0.340 |
Why?
|
| Sequence Alignment | 7 | 2005 | 2176 | 0.340 |
Why?
|
| Fibroblasts | 6 | 2021 | 4087 | 0.340 |
Why?
|
| Albinism | 1 | 2019 | 24 | 0.340 |
Why?
|
| Craniofacial Abnormalities | 2 | 2023 | 315 | 0.340 |
Why?
|
| Movement Disorders | 1 | 2023 | 459 | 0.340 |
Why?
|
| Adrenocorticotropic Hormone | 3 | 2001 | 617 | 0.340 |
Why?
|
| Genetic Markers | 4 | 2013 | 2608 | 0.330 |
Why?
|
| Spastic Paraplegia, Hereditary | 2 | 2023 | 168 | 0.330 |
Why?
|
| Pedigree | 5 | 2024 | 4578 | 0.330 |
Why?
|
| Depression | 6 | 2021 | 8052 | 0.330 |
Why?
|
| Retrospective Studies | 33 | 2023 | 79982 | 0.330 |
Why?
|
| Bariatric Surgery | 1 | 2019 | 986 | 0.320 |
Why?
|
| Biotechnology | 1 | 2011 | 281 | 0.320 |
Why?
|
| Muscle, Skeletal | 14 | 2024 | 4902 | 0.320 |
Why?
|
| Geography | 2 | 2010 | 658 | 0.320 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2012 | 786 | 0.320 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2020 | 5272 | 0.320 |
Why?
|
| Acids | 1 | 2019 | 125 | 0.320 |
Why?
|
| Cooperative Behavior | 4 | 2012 | 1501 | 0.320 |
Why?
|
| Lysosomal Storage Diseases | 1 | 2019 | 79 | 0.320 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2016 | 4342 | 0.310 |
Why?
|
| American Recovery and Reinvestment Act | 2 | 2020 | 72 | 0.310 |
Why?
|
| Chromosomes, Mammalian | 2 | 2007 | 146 | 0.310 |
Why?
|
| Schizophrenia | 7 | 2022 | 6913 | 0.310 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 3023 | 0.310 |
Why?
|
| Membrane Transport Proteins | 1 | 2024 | 1034 | 0.310 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2008 | 178 | 0.310 |
Why?
|
| Publications | 1 | 2010 | 194 | 0.310 |
Why?
|
| Huntington Disease | 5 | 2014 | 1141 | 0.310 |
Why?
|
| Hospitalization | 14 | 2022 | 10633 | 0.310 |
Why?
|
| Mobile Health Units | 1 | 2009 | 92 | 0.310 |
Why?
|
| Eye Abnormalities | 1 | 2020 | 241 | 0.310 |
Why?
|
| Suicide | 1 | 2019 | 1593 | 0.300 |
Why?
|
| Leukocytes | 2 | 2017 | 2025 | 0.300 |
Why?
|
| Communication | 6 | 2020 | 3842 | 0.300 |
Why?
|
| Chloride Channels | 1 | 2019 | 221 | 0.300 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2010 | 338 | 0.300 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2023 | 2248 | 0.290 |
Why?
|
| Lipomatosis | 1 | 2018 | 112 | 0.290 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2018 | 84 | 0.290 |
Why?
|
| Models, Theoretical | 5 | 2017 | 3560 | 0.290 |
Why?
|
| Research Personnel | 1 | 2012 | 582 | 0.290 |
Why?
|
| Pain, Postoperative | 1 | 2018 | 1715 | 0.290 |
Why?
|
| Heart Conduction System | 1 | 2013 | 1011 | 0.290 |
Why?
|
| Time | 4 | 2001 | 543 | 0.290 |
Why?
|
| Patient Care | 1 | 2013 | 621 | 0.290 |
Why?
|
| RNA, Messenger | 19 | 2023 | 12761 | 0.290 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 1666 | 0.290 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2019 | 706 | 0.290 |
Why?
|
| Classification | 1 | 2007 | 127 | 0.290 |
Why?
|
| Carrier Proteins | 3 | 2023 | 4937 | 0.290 |
Why?
|
| Heterozygote | 6 | 2023 | 2797 | 0.290 |
Why?
|
| Informed Consent | 4 | 2011 | 1003 | 0.280 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2016 | 1309 | 0.280 |
Why?
|
| Antigens, Human Platelet | 2 | 2018 | 41 | 0.280 |
Why?
|
| Ear, External | 1 | 2007 | 164 | 0.280 |
Why?
|
| Databases, Protein | 3 | 2006 | 387 | 0.280 |
Why?
|
| Publishing | 4 | 2021 | 832 | 0.280 |
Why?
|
| Commerce | 1 | 2012 | 603 | 0.280 |
Why?
|
| Bone Marrow Diseases | 1 | 2018 | 232 | 0.270 |
Why?
|
| Micronucleus, Germline | 1 | 2006 | 6 | 0.270 |
Why?
|
| Vocabulary, Controlled | 5 | 2012 | 167 | 0.270 |
Why?
|
| Mutation, Missense | 6 | 2023 | 2565 | 0.270 |
Why?
|
| Vitamin A | 1 | 2009 | 613 | 0.270 |
Why?
|
| Trinucleotide Repeats | 3 | 2013 | 257 | 0.270 |
Why?
|
| Boston | 15 | 2018 | 9297 | 0.270 |
Why?
|
| Aged | 49 | 2023 | 167889 | 0.270 |
Why?
|
| Models, Biological | 12 | 2013 | 9460 | 0.270 |
Why?
|
| Signal Transduction | 15 | 2020 | 23342 | 0.270 |
Why?
|
| Gene Regulatory Networks | 6 | 2015 | 1740 | 0.260 |
Why?
|
| Mice | 37 | 2024 | 81107 | 0.260 |
Why?
|
| Cardiomyopathies | 3 | 2024 | 1945 | 0.260 |
Why?
|
| Blood Group Antigens | 2 | 2018 | 187 | 0.260 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2016 | 3227 | 0.260 |
Why?
|
| Terminology as Topic | 1 | 2013 | 1533 | 0.260 |
Why?
|
| Mosaicism | 2 | 2024 | 465 | 0.260 |
Why?
|
| PubMed | 2 | 2019 | 128 | 0.260 |
Why?
|
| Government Regulation | 3 | 2017 | 524 | 0.250 |
Why?
|
| Diabetes Mellitus | 8 | 2015 | 5815 | 0.250 |
Why?
|
| Pluripotent Stem Cells | 1 | 2012 | 792 | 0.250 |
Why?
|
| Decision Making | 4 | 2019 | 3909 | 0.250 |
Why?
|
| Depressive Disorder | 5 | 2021 | 3726 | 0.250 |
Why?
|
| Attitude to Computers | 6 | 2012 | 195 | 0.250 |
Why?
|
| Clostridium Infections | 3 | 2021 | 557 | 0.250 |
Why?
|
| Plant Extracts | 2 | 2011 | 489 | 0.250 |
Why?
|
| Risk Factors | 35 | 2021 | 73716 | 0.250 |
Why?
|
| Cell Hypoxia | 1 | 2007 | 656 | 0.250 |
Why?
|
| GTP Phosphohydrolases | 1 | 2018 | 516 | 0.250 |
Why?
|
| rab GTP-Binding Proteins | 2 | 2024 | 250 | 0.250 |
Why?
|
| Bibliometrics | 1 | 2009 | 349 | 0.250 |
Why?
|
| Molecular Sequence Annotation | 4 | 2017 | 524 | 0.250 |
Why?
|
| Workflow | 2 | 2021 | 850 | 0.250 |
Why?
|
| Area Under Curve | 5 | 2021 | 1632 | 0.240 |
Why?
|
| Lipids | 4 | 2024 | 3326 | 0.240 |
Why?
|
| Insurance, Health | 6 | 2021 | 2482 | 0.240 |
Why?
|
| Drug Repositioning | 2 | 2018 | 231 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2020 | 4021 | 0.240 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 4540 | 0.240 |
Why?
|
| Periodicals as Topic | 3 | 2012 | 1459 | 0.230 |
Why?
|
| Immunity, Innate | 1 | 2016 | 3047 | 0.230 |
Why?
|
| National Institutes of Health (U.S.) | 5 | 2018 | 791 | 0.230 |
Why?
|
| DNA Methylation | 3 | 2019 | 4374 | 0.230 |
Why?
|
| Risk Assessment | 15 | 2021 | 23819 | 0.230 |
Why?
|
| Mitochondria | 4 | 2019 | 3584 | 0.230 |
Why?
|
| Drosophila Proteins | 2 | 2024 | 1698 | 0.230 |
Why?
|
| Genitalia | 2 | 2019 | 113 | 0.230 |
Why?
|
| rab5 GTP-Binding Proteins | 1 | 2023 | 48 | 0.230 |
Why?
|
| Altruism | 1 | 2005 | 205 | 0.220 |
Why?
|
| Nutrition Surveys | 4 | 2022 | 1716 | 0.220 |
Why?
|
| Pharmaceutical Preparations | 3 | 2020 | 1088 | 0.220 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2014 | 82 | 0.220 |
Why?
|
| Lysosomes | 1 | 2019 | 919 | 0.220 |
Why?
|
| Diagnostic Imaging | 4 | 2022 | 3524 | 0.220 |
Why?
|
| Schizophrenic Psychology | 2 | 2015 | 1646 | 0.220 |
Why?
|
| Leukoencephalitis, Acute Hemorrhagic | 1 | 2023 | 19 | 0.220 |
Why?
|
| Hydrocortisone | 3 | 2001 | 1802 | 0.220 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 4873 | 0.220 |
Why?
|
| Heart Rate | 3 | 2013 | 4166 | 0.220 |
Why?
|
| APACHE | 1 | 2004 | 267 | 0.220 |
Why?
|
| Health Services Research | 2 | 2009 | 1812 | 0.220 |
Why?
|
| Osteochondrodysplasias | 2 | 2019 | 182 | 0.220 |
Why?
|
| Social Values | 1 | 2024 | 225 | 0.210 |
Why?
|
| Referral and Consultation | 3 | 2021 | 3579 | 0.210 |
Why?
|
| Chromosome Mapping | 3 | 2006 | 4624 | 0.210 |
Why?
|
| Chromosomal Instability | 2 | 2019 | 178 | 0.210 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2007 | 316 | 0.210 |
Why?
|
| Muscle Proteins | 2 | 2006 | 1150 | 0.210 |
Why?
|
| Metabolic Diseases | 2 | 2021 | 682 | 0.210 |
Why?
|
| Physicians | 5 | 2018 | 4578 | 0.210 |
Why?
|
| Environmental Exposure | 2 | 2017 | 4411 | 0.210 |
Why?
|
| Health Policy | 1 | 2015 | 2675 | 0.210 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 3 | 2011 | 487 | 0.210 |
Why?
|
| Emergency Service, Hospital | 9 | 2023 | 7801 | 0.210 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2007 | 530 | 0.210 |
Why?
|
| Muscle Hypotonia | 3 | 2023 | 160 | 0.210 |
Why?
|
| Eukaryotic Cells | 1 | 2004 | 195 | 0.210 |
Why?
|
| Colorectal Neoplasms | 4 | 2016 | 6841 | 0.210 |
Why?
|
| Proteinuria | 1 | 2005 | 594 | 0.210 |
Why?
|
| Antidepressive Agents | 5 | 2016 | 2889 | 0.210 |
Why?
|
| Phosphatidylinositols | 1 | 2023 | 282 | 0.200 |
Why?
|
| Logistic Models | 13 | 2017 | 13222 | 0.200 |
Why?
|
| Serum Amyloid A Protein | 1 | 2022 | 127 | 0.200 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2007 | 633 | 0.200 |
Why?
|
| Privacy | 5 | 2022 | 233 | 0.200 |
Why?
|
| Models, Statistical | 8 | 2019 | 5068 | 0.200 |
Why?
|
| Insurance | 2 | 2021 | 113 | 0.200 |
Why?
|
| Mental Disorders | 7 | 2021 | 6802 | 0.200 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2013 | 1842 | 0.200 |
Why?
|
| RNA, Neoplasm | 5 | 2006 | 749 | 0.200 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 2001 | 361 | 0.200 |
Why?
|
| Public Health Practice | 2 | 2021 | 218 | 0.200 |
Why?
|
| Public Health Administration | 2 | 2002 | 242 | 0.200 |
Why?
|
| X Chromosome | 1 | 2005 | 815 | 0.200 |
Why?
|
| Multigene Family | 4 | 2006 | 1076 | 0.200 |
Why?
|
| Endocannabinoids | 1 | 2022 | 111 | 0.200 |
Why?
|
| Ikaros Transcription Factor | 1 | 2023 | 231 | 0.190 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 3 | 2015 | 184 | 0.190 |
Why?
|
| Health Level Seven | 3 | 2016 | 35 | 0.190 |
Why?
|
| Sex Factors | 5 | 2019 | 10497 | 0.190 |
Why?
|
| DNA-Binding Proteins | 5 | 2023 | 9574 | 0.190 |
Why?
|
| Nephrotic Syndrome | 1 | 2005 | 391 | 0.190 |
Why?
|
| History, 21st Century | 3 | 2019 | 1569 | 0.190 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2020 | 2419 | 0.190 |
Why?
|
| Infant, Premature | 4 | 2020 | 2093 | 0.190 |
Why?
|
| Statistics as Topic | 4 | 2014 | 2357 | 0.190 |
Why?
|
| Bioterrorism | 1 | 2002 | 144 | 0.190 |
Why?
|
| Bone Morphogenetic Proteins | 3 | 2021 | 841 | 0.190 |
Why?
|
| Peptides | 4 | 2018 | 4340 | 0.190 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2021 | 85 | 0.190 |
Why?
|
| Transcription, Genetic | 12 | 2012 | 7590 | 0.180 |
Why?
|
| Sleep | 1 | 2017 | 4745 | 0.180 |
Why?
|
| Apraxias | 1 | 2021 | 59 | 0.180 |
Why?
|
| Syndactyly | 1 | 2021 | 72 | 0.180 |
Why?
|
| Sex Characteristics | 2 | 2022 | 2621 | 0.180 |
Why?
|
| Neoplasms | 13 | 2019 | 21990 | 0.180 |
Why?
|
| Nerve Tissue Proteins | 6 | 2017 | 4406 | 0.180 |
Why?
|
| Ethers | 1 | 2020 | 73 | 0.180 |
Why?
|
| Aging | 3 | 2017 | 8650 | 0.180 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2020 | 87 | 0.180 |
Why?
|
| DNA Probes | 4 | 2005 | 543 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2008 | 2913 | 0.180 |
Why?
|
| Population Surveillance | 5 | 2014 | 2599 | 0.180 |
Why?
|
| Growth Differentiation Factors | 1 | 2021 | 99 | 0.180 |
Why?
|
| Multivariate Analysis | 11 | 2021 | 12047 | 0.180 |
Why?
|
| Ribonuclease III | 1 | 2022 | 279 | 0.180 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 3 | 2015 | 367 | 0.180 |
Why?
|
| Search Engine | 2 | 2018 | 140 | 0.180 |
Why?
|
| Vitamin D | 4 | 2015 | 3283 | 0.180 |
Why?
|
| Psychotic Disorders | 3 | 2022 | 3197 | 0.180 |
Why?
|
| Creatinine | 3 | 2022 | 1892 | 0.170 |
Why?
|
| Drosophila melanogaster | 4 | 2021 | 1708 | 0.170 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 2001 | 0.170 |
Why?
|
| Research | 6 | 2023 | 1975 | 0.170 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 2305 | 0.170 |
Why?
|
| Prognosis | 15 | 2021 | 29493 | 0.170 |
Why?
|
| Cell Differentiation | 3 | 2013 | 11470 | 0.170 |
Why?
|
| Medical Informatics Computing | 1 | 2019 | 24 | 0.170 |
Why?
|
| Research Subjects | 2 | 2012 | 249 | 0.170 |
Why?
|
| Systems Biology | 3 | 2008 | 482 | 0.170 |
Why?
|
| Up-Regulation | 7 | 2013 | 4113 | 0.170 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2022 | 1903 | 0.170 |
Why?
|
| History, 20th Century | 2 | 2019 | 2770 | 0.170 |
Why?
|
| Hospital Communication Systems | 1 | 2000 | 48 | 0.170 |
Why?
|
| Growth Disorders | 2 | 1996 | 653 | 0.170 |
Why?
|
| Risk | 9 | 2024 | 9590 | 0.170 |
Why?
|
| Quality Improvement | 2 | 2018 | 3793 | 0.170 |
Why?
|
| Molecular Structure | 3 | 2021 | 1865 | 0.170 |
Why?
|
| Saccharomyces cerevisiae | 8 | 2022 | 2695 | 0.170 |
Why?
|
| Prefrontal Cortex | 1 | 2020 | 2209 | 0.170 |
Why?
|
| eIF-2 Kinase | 1 | 2020 | 144 | 0.170 |
Why?
|
| Microarray Analysis | 3 | 2012 | 745 | 0.170 |
Why?
|
| Asthma | 8 | 2011 | 6172 | 0.170 |
Why?
|
| Hypothyroidism | 2 | 2013 | 665 | 0.170 |
Why?
|
| Methyltransferases | 1 | 2022 | 374 | 0.160 |
Why?
|
| Colonoscopy | 2 | 2019 | 1385 | 0.160 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 368 | 0.160 |
Why?
|
| Laboratories, Hospital | 1 | 2000 | 192 | 0.160 |
Why?
|
| Pregnancy, Multiple | 1 | 2020 | 215 | 0.160 |
Why?
|
| Epigenomics | 2 | 2017 | 936 | 0.160 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 1 | 2019 | 62 | 0.160 |
Why?
|
| Therapy, Computer-Assisted | 3 | 1997 | 266 | 0.160 |
Why?
|
| Postoperative Complications | 2 | 2019 | 15532 | 0.160 |
Why?
|
| Child Abuse, Sexual | 1 | 2001 | 394 | 0.160 |
Why?
|
| Tissue Banks | 3 | 2012 | 184 | 0.160 |
Why?
|
| Odds Ratio | 7 | 2022 | 9624 | 0.160 |
Why?
|
| Child Abuse | 1 | 2017 | 1068 | 0.160 |
Why?
|
| Fragile X Syndrome | 1 | 2020 | 116 | 0.160 |
Why?
|
| Cells, Cultured | 9 | 2021 | 18941 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 5 | 2018 | 1651 | 0.150 |
Why?
|
| Biopsy | 5 | 2019 | 6758 | 0.150 |
Why?
|
| Semantics | 2 | 2019 | 601 | 0.150 |
Why?
|
| Apoptosis | 4 | 2011 | 9469 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2000 | 714 | 0.150 |
Why?
|
| Embryo, Mammalian | 1 | 2004 | 1674 | 0.150 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2018 | 65 | 0.150 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2019 | 100 | 0.150 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2018 | 53 | 0.150 |
Why?
|
| Rett Syndrome | 1 | 2019 | 164 | 0.150 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2018 | 100 | 0.150 |
Why?
|
| Hyperbilirubinemia | 1 | 1998 | 74 | 0.150 |
Why?
|
| Insulin Resistance | 2 | 2009 | 3941 | 0.150 |
Why?
|
| Disease Management | 1 | 2018 | 2495 | 0.150 |
Why?
|
| Computer Literacy | 1 | 1997 | 44 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 5 | 2011 | 5779 | 0.150 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2022 | 2237 | 0.150 |
Why?
|
| Disease Outbreaks | 4 | 2020 | 1756 | 0.150 |
Why?
|
| Voice | 1 | 2001 | 268 | 0.150 |
Why?
|
| Neonatal Screening | 1 | 2002 | 594 | 0.140 |
Why?
|
| Remote Consultation | 1 | 2000 | 233 | 0.140 |
Why?
|
| Mifepristone | 1 | 2018 | 150 | 0.140 |
Why?
|
| Quantitative Trait Loci | 1 | 2005 | 2100 | 0.140 |
Why?
|
| Laboratories | 2 | 2022 | 460 | 0.140 |
Why?
|
| Trazodone | 1 | 2017 | 68 | 0.140 |
Why?
|
| Suicide, Attempted | 2 | 2023 | 1383 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20499 | 0.140 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 3068 | 0.140 |
Why?
|
| Neurons | 4 | 2013 | 9419 | 0.140 |
Why?
|
| Self Report | 2 | 2020 | 3709 | 0.140 |
Why?
|
| Leukoencephalopathies | 1 | 2020 | 249 | 0.140 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 462 | 0.140 |
Why?
|
| Muscular Dystrophy, Duchenne | 3 | 2005 | 268 | 0.140 |
Why?
|
| Patient Compliance | 1 | 2007 | 2685 | 0.140 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2020 | 353 | 0.140 |
Why?
|
| Long QT Syndrome | 1 | 2021 | 465 | 0.140 |
Why?
|
| Unified Medical Language System | 3 | 2019 | 89 | 0.140 |
Why?
|
| Premature Birth | 2 | 2020 | 1766 | 0.140 |
Why?
|
| Hearing | 1 | 2020 | 501 | 0.140 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2000 | 458 | 0.140 |
Why?
|
| Prevalence | 7 | 2022 | 15641 | 0.140 |
Why?
|
| Proportional Hazards Models | 6 | 2022 | 12400 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 5 | 2008 | 6128 | 0.130 |
Why?
|
| Fathers | 1 | 2019 | 377 | 0.130 |
Why?
|
| Hyperlipidemias | 2 | 2018 | 771 | 0.130 |
Why?
|
| Glioblastoma | 2 | 2008 | 3480 | 0.130 |
Why?
|
| Decision Support Techniques | 4 | 2014 | 1991 | 0.130 |
Why?
|
| CpG Islands | 3 | 2011 | 1221 | 0.130 |
Why?
|
| Hyperandrogenism | 1 | 1996 | 39 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 2 | 2022 | 2152 | 0.130 |
Why?
|
| Patient Discharge | 2 | 2015 | 3428 | 0.130 |
Why?
|
| Probability | 6 | 2019 | 2461 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2024 | 3613 | 0.130 |
Why?
|
| Social Control, Formal | 1 | 2016 | 108 | 0.130 |
Why?
|
| Hearing Loss | 1 | 2023 | 781 | 0.130 |
Why?
|
| Quality Control | 1 | 2018 | 825 | 0.130 |
Why?
|
| Subcutaneous Fat | 1 | 2019 | 393 | 0.130 |
Why?
|
| ABO Blood-Group System | 1 | 2018 | 367 | 0.130 |
Why?
|
| Weight Gain | 2 | 2017 | 2345 | 0.130 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 1994 | 0.130 |
Why?
|
| Povidone-Iodine | 1 | 1995 | 55 | 0.130 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2019 | 258 | 0.130 |
Why?
|
| Progestins | 1 | 2017 | 302 | 0.130 |
Why?
|
| Skin Care | 1 | 1995 | 57 | 0.130 |
Why?
|
| C-Reactive Protein | 3 | 2017 | 3811 | 0.130 |
Why?
|
| Cell Proliferation | 6 | 2015 | 10416 | 0.130 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2011 | 1055 | 0.130 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 2022 | 1851 | 0.130 |
Why?
|
| Eye | 1 | 2019 | 710 | 0.130 |
Why?
|
| Amyloidosis | 1 | 2022 | 817 | 0.130 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2021 | 453 | 0.130 |
Why?
|
| Intensive Care Units | 4 | 2004 | 3732 | 0.130 |
Why?
|
| Information Services | 3 | 2017 | 235 | 0.130 |
Why?
|
| TYK2 Kinase | 1 | 2015 | 37 | 0.120 |
Why?
|
| Species Specificity | 5 | 2006 | 2416 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2008 | 2293 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2022 | 12076 | 0.120 |
Why?
|
| Pituitary-Adrenal System | 2 | 1999 | 552 | 0.120 |
Why?
|
| Cadherins | 1 | 2019 | 898 | 0.120 |
Why?
|
| Patient-Centered Care | 2 | 2016 | 1415 | 0.120 |
Why?
|
| Drosophila | 4 | 2024 | 1491 | 0.120 |
Why?
|
| Epidemiologic Studies | 2 | 2015 | 670 | 0.120 |
Why?
|
| Forms and Records Control | 2 | 2008 | 158 | 0.120 |
Why?
|
| Autoantibodies | 3 | 2013 | 2118 | 0.120 |
Why?
|
| Corpus Callosum | 1 | 2019 | 749 | 0.120 |
Why?
|
| Primary Health Care | 3 | 2017 | 4651 | 0.120 |
Why?
|
| Puberty, Precocious | 1 | 1996 | 164 | 0.120 |
Why?
|
| Models, Molecular | 2 | 2019 | 5411 | 0.120 |
Why?
|
| Wounds and Injuries | 2 | 2019 | 2475 | 0.120 |
Why?
|
| Hemochromatosis | 1 | 2016 | 174 | 0.120 |
Why?
|
| Protein Transport | 1 | 2020 | 1963 | 0.120 |
Why?
|
| Cell Cycle | 5 | 2011 | 2930 | 0.120 |
Why?
|
| Embryonic Stem Cells | 2 | 2012 | 1262 | 0.120 |
Why?
|
| Protein Subunits | 1 | 2018 | 942 | 0.120 |
Why?
|
| Health Planning Guidelines | 1 | 2015 | 151 | 0.120 |
Why?
|
| United States Food and Drug Administration | 3 | 2019 | 1658 | 0.120 |
Why?
|
| Aftercare | 1 | 2000 | 909 | 0.120 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2021 | 831 | 0.120 |
Why?
|
| Incidence | 9 | 2021 | 21217 | 0.120 |
Why?
|
| Sequence Analysis | 1 | 2015 | 240 | 0.120 |
Why?
|
| Selection Bias | 1 | 2016 | 357 | 0.110 |
Why?
|
| Transcriptional Activation | 1 | 2020 | 1753 | 0.110 |
Why?
|
| Point-of-Care Systems | 3 | 2016 | 1201 | 0.110 |
Why?
|
| Neuroma, Acoustic | 1 | 2018 | 459 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 2796 | 0.110 |
Why?
|
| Least-Squares Analysis | 3 | 2021 | 369 | 0.110 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 1999 | 700 | 0.110 |
Why?
|
| Microfilament Proteins | 1 | 2019 | 1133 | 0.110 |
Why?
|
| Brain Diseases | 1 | 2023 | 1541 | 0.110 |
Why?
|
| Myocarditis | 1 | 2021 | 765 | 0.110 |
Why?
|
| Biological Products | 1 | 2023 | 905 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 8 | 2024 | 22008 | 0.110 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 933 | 0.110 |
Why?
|
| Mass Screening | 1 | 2009 | 5413 | 0.110 |
Why?
|
| Genetic Pleiotropy | 1 | 2015 | 181 | 0.110 |
Why?
|
| Vitamin D Deficiency | 2 | 2013 | 1377 | 0.110 |
Why?
|
| Amino Acid Transport System ASC | 1 | 2023 | 16 | 0.110 |
Why?
|
| Biological Specimen Banks | 2 | 2020 | 782 | 0.110 |
Why?
|
| Anonymous Testing | 1 | 2013 | 9 | 0.110 |
Why?
|
| Geographic Information Systems | 2 | 2006 | 281 | 0.110 |
Why?
|
| Sensitivity and Specificity | 12 | 2021 | 14638 | 0.110 |
Why?
|
| Predictive Value of Tests | 9 | 2014 | 15209 | 0.110 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2015 | 321 | 0.110 |
Why?
|
| Hearing Disorders | 1 | 2013 | 126 | 0.110 |
Why?
|
| Counseling | 1 | 2021 | 1540 | 0.110 |
Why?
|
| DNA Damage | 2 | 2019 | 2439 | 0.110 |
Why?
|
| Anti-Infective Agents, Local | 1 | 1995 | 247 | 0.110 |
Why?
|
| Feasibility Studies | 4 | 2019 | 5195 | 0.110 |
Why?
|
| Myopathies, Nemaline | 2 | 2004 | 73 | 0.110 |
Why?
|
| Membrane Proteins | 2 | 2024 | 7841 | 0.110 |
Why?
|
| Immunologic Factors | 3 | 2023 | 1584 | 0.110 |
Why?
|
| Data Display | 1 | 1994 | 174 | 0.110 |
Why?
|
| Genetic Linkage | 2 | 2012 | 2381 | 0.110 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 15782 | 0.110 |
Why?
|
| Gait | 2 | 2023 | 812 | 0.110 |
Why?
|
| Menarche | 1 | 1996 | 529 | 0.110 |
Why?
|
| Acoustic Stimulation | 1 | 2017 | 1232 | 0.110 |
Why?
|
| DNA | 3 | 2019 | 7199 | 0.110 |
Why?
|
| Parkinson Disease | 2 | 2021 | 2863 | 0.110 |
Why?
|
| Names | 1 | 2013 | 54 | 0.110 |
Why?
|
| Actinin | 1 | 2024 | 163 | 0.110 |
Why?
|
| Cell Line | 9 | 2020 | 15594 | 0.110 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2024 | 177 | 0.110 |
Why?
|
| Blood Sedimentation | 1 | 2014 | 234 | 0.110 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 3705 | 0.110 |
Why?
|
| Hospitals, Pediatric | 7 | 2002 | 1853 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 1335 | 0.100 |
Why?
|
| Amino Acid Sequence | 3 | 2019 | 13447 | 0.100 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2021 | 786 | 0.100 |
Why?
|
| RNA, Ribosomal | 1 | 2013 | 226 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 2 | 2019 | 1957 | 0.100 |
Why?
|
| Brain | 6 | 2024 | 26950 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2016 | 2496 | 0.100 |
Why?
|
| Prospective Studies | 9 | 2021 | 54108 | 0.100 |
Why?
|
| Principal Component Analysis | 4 | 2009 | 940 | 0.100 |
Why?
|
| DNA, Complementary | 3 | 2005 | 1991 | 0.100 |
Why?
|
| Hypoglycemia | 1 | 2000 | 881 | 0.100 |
Why?
|
| Heart Arrest, Induced | 2 | 2004 | 357 | 0.100 |
Why?
|
| Chemokine CXCL10 | 1 | 2013 | 316 | 0.100 |
Why?
|
| Interdisciplinary Communication | 2 | 2015 | 931 | 0.100 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2014 | 431 | 0.100 |
Why?
|
| Brain Stem | 1 | 2017 | 857 | 0.100 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 3 | 2021 | 3701 | 0.100 |
Why?
|
| Cell Lineage | 2 | 2020 | 2533 | 0.100 |
Why?
|
| Down-Regulation | 4 | 2013 | 2903 | 0.100 |
Why?
|
| Medulloblastoma | 2 | 2015 | 678 | 0.100 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 5382 | 0.100 |
Why?
|
| RNA | 5 | 2019 | 2716 | 0.100 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2014 | 177 | 0.100 |
Why?
|
| Chromosomes, Human, Y | 1 | 2013 | 161 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 4313 | 0.100 |
Why?
|
| Human Genome Project | 2 | 2018 | 199 | 0.100 |
Why?
|
| Sex Ratio | 1 | 2012 | 107 | 0.100 |
Why?
|
| Early Diagnosis | 3 | 2016 | 1177 | 0.100 |
Why?
|
| Sequence Inversion | 1 | 2021 | 4 | 0.100 |
Why?
|
| Pregnancy | 11 | 2021 | 29720 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2021 | 8945 | 0.100 |
Why?
|
| Research Report | 1 | 2015 | 367 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2017 | 6012 | 0.100 |
Why?
|
| Base Sequence | 7 | 2022 | 12437 | 0.100 |
Why?
|
| Myocardial Infarction | 2 | 2009 | 11422 | 0.100 |
Why?
|
| Ataxia | 2 | 2020 | 306 | 0.100 |
Why?
|
| Health Expenditures | 2 | 2021 | 2342 | 0.100 |
Why?
|
| Epidemiologic Research Design | 1 | 2015 | 368 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2017 | 1187 | 0.100 |
Why?
|
| Anxiety Disorders | 2 | 2013 | 2714 | 0.100 |
Why?
|
| Antibodies, Antinuclear | 1 | 2013 | 344 | 0.100 |
Why?
|
| Axons | 1 | 2019 | 1674 | 0.100 |
Why?
|
| Curriculum | 4 | 2019 | 3715 | 0.100 |
Why?
|
| Eligibility Determination | 1 | 2015 | 419 | 0.090 |
Why?
|
| Patient Care Planning | 1 | 1997 | 906 | 0.090 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2024 | 477 | 0.090 |
Why?
|
| Protein Conformation | 1 | 2019 | 3967 | 0.090 |
Why?
|
| Terpenes | 1 | 2011 | 96 | 0.090 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2014 | 489 | 0.090 |
Why?
|
| Oxygen | 4 | 2019 | 4190 | 0.090 |
Why?
|
| Sjogren's Syndrome | 1 | 2013 | 234 | 0.090 |
Why?
|
| Diabetic Retinopathy | 1 | 2020 | 1267 | 0.090 |
Why?
|
| Reaction Time | 1 | 2017 | 2076 | 0.090 |
Why?
|
| RNA Editing | 1 | 2012 | 151 | 0.090 |
Why?
|
| Truth Disclosure | 2 | 2012 | 432 | 0.090 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 496 | 0.090 |
Why?
|
| Pattern Recognition, Automated | 2 | 2008 | 994 | 0.090 |
Why?
|
| Uncertainty | 1 | 2016 | 750 | 0.090 |
Why?
|
| RNA Splice Sites | 1 | 2022 | 211 | 0.090 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2007 | 1093 | 0.090 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2019 | 930 | 0.090 |
Why?
|
| Cataract | 1 | 2017 | 827 | 0.090 |
Why?
|
| Smoking | 1 | 2007 | 9036 | 0.090 |
Why?
|
| Universities | 2 | 2019 | 993 | 0.090 |
Why?
|
| Follow-Up Studies | 10 | 2019 | 39018 | 0.090 |
Why?
|
| Parturition | 1 | 2014 | 446 | 0.090 |
Why?
|
| Family Relations | 1 | 2023 | 317 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2024 | 2870 | 0.090 |
Why?
|
| Paroxetine | 1 | 2011 | 182 | 0.090 |
Why?
|
| Regression Analysis | 5 | 2021 | 6336 | 0.090 |
Why?
|
| Diabetes Complications | 2 | 2009 | 1317 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2009 | 4567 | 0.090 |
Why?
|
| Electronics | 2 | 2009 | 315 | 0.090 |
Why?
|
| International Cooperation | 2 | 2017 | 1429 | 0.090 |
Why?
|
| Technology | 1 | 2012 | 292 | 0.090 |
Why?
|
| Health Occupations | 1 | 2012 | 222 | 0.090 |
Why?
|
| New England | 4 | 2014 | 1051 | 0.090 |
Why?
|
| Time Factors | 11 | 2019 | 39815 | 0.090 |
Why?
|
| Metagenomics | 1 | 2014 | 457 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2008 | 255 | 0.090 |
Why?
|
| Linear Models | 3 | 2017 | 5857 | 0.090 |
Why?
|
| Lipoproteins, LDL | 1 | 2013 | 640 | 0.090 |
Why?
|
| Neostriatum | 1 | 2011 | 246 | 0.090 |
Why?
|
| Brain Neoplasms | 2 | 2008 | 8981 | 0.090 |
Why?
|
| Cerebellar Neoplasms | 1 | 2015 | 586 | 0.090 |
Why?
|
| Hospital Mortality | 1 | 2004 | 5243 | 0.090 |
Why?
|
| Qualitative Research | 2 | 2023 | 2975 | 0.090 |
Why?
|
| Genes, Fungal | 2 | 2001 | 439 | 0.090 |
Why?
|
| Germ Cells | 1 | 2024 | 634 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 4845 | 0.080 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2018 | 2387 | 0.080 |
Why?
|
| Respiration, Artificial | 3 | 1997 | 2619 | 0.080 |
Why?
|
| HEK293 Cells | 2 | 2024 | 4258 | 0.080 |
Why?
|
| Ethics, Medical | 2 | 2012 | 783 | 0.080 |
Why?
|
| Adenosine Triphosphatases | 1 | 2024 | 832 | 0.080 |
Why?
|
| Limbic System | 1 | 2012 | 419 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2021 | 3171 | 0.080 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2011 | 324 | 0.080 |
Why?
|
| Neurofibromin 1 | 2 | 2008 | 190 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2022 | 10075 | 0.080 |
Why?
|
| Public Health Informatics | 2 | 2007 | 109 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 2 | 2008 | 3795 | 0.080 |
Why?
|
| Expressed Sequence Tags | 4 | 2003 | 250 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 2125 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2021 | 2040 | 0.080 |
Why?
|
| Drug Costs | 1 | 2017 | 1179 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2022 | 2001 | 0.080 |
Why?
|
| Blood | 1 | 2011 | 585 | 0.080 |
Why?
|
| Serine | 1 | 2023 | 828 | 0.080 |
Why?
|
| Pravastatin | 1 | 2011 | 392 | 0.080 |
Why?
|
| Diarylheptanoids | 1 | 2008 | 2 | 0.080 |
Why?
|
| Israel | 2 | 2021 | 721 | 0.080 |
Why?
|
| Ribonucleoprotein, U5 Small Nuclear | 1 | 2018 | 8 | 0.080 |
Why?
|
| Professional-Family Relations | 1 | 2023 | 495 | 0.080 |
Why?
|
| Italy | 1 | 2011 | 838 | 0.080 |
Why?
|
| Codon | 1 | 2011 | 601 | 0.080 |
Why?
|
| Polymorphism, Genetic | 3 | 2019 | 4283 | 0.080 |
Why?
|
| Ethics, Research | 1 | 2010 | 176 | 0.080 |
Why?
|
| Lipoproteins | 1 | 2013 | 881 | 0.080 |
Why?
|
| Rats | 6 | 2009 | 23681 | 0.080 |
Why?
|
| Peptide Elongation Factors | 1 | 2018 | 62 | 0.080 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2008 | 617 | 0.080 |
Why?
|
| Decision Trees | 2 | 2001 | 504 | 0.080 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2018 | 1079 | 0.080 |
Why?
|
| DNA Mutational Analysis | 2 | 2024 | 4107 | 0.080 |
Why?
|
| Medicare Part C | 1 | 2013 | 322 | 0.080 |
Why?
|
| Pathology, Surgical | 2 | 2007 | 151 | 0.080 |
Why?
|
| Feedback, Physiological | 1 | 2011 | 475 | 0.080 |
Why?
|
| Europe | 2 | 2020 | 3415 | 0.080 |
Why?
|
| Reimbursement, Incentive | 1 | 2013 | 540 | 0.080 |
Why?
|
| Garcinia | 1 | 2008 | 3 | 0.080 |
Why?
|
| Lung | 6 | 2009 | 9979 | 0.080 |
Why?
|
| Autophagy | 1 | 2016 | 1322 | 0.080 |
Why?
|
| Activating Transcription Factor 3 | 1 | 2008 | 53 | 0.080 |
Why?
|
| Radio | 1 | 2007 | 9 | 0.080 |
Why?
|
| Globins | 1 | 2009 | 403 | 0.080 |
Why?
|
| Evolution, Molecular | 5 | 2019 | 1884 | 0.080 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 25931 | 0.080 |
Why?
|
| Intelligence | 1 | 2013 | 921 | 0.080 |
Why?
|
| Research Support as Topic | 1 | 2012 | 697 | 0.080 |
Why?
|
| Cell Line, Transformed | 1 | 2009 | 869 | 0.070 |
Why?
|
| Domestic Violence | 1 | 2009 | 181 | 0.070 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 162 | 0.070 |
Why?
|
| Electronics, Medical | 1 | 2007 | 72 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 3 | 2004 | 7366 | 0.070 |
Why?
|
| DNA Modification Methylases | 1 | 2008 | 209 | 0.070 |
Why?
|
| Stress, Mechanical | 3 | 2007 | 1664 | 0.070 |
Why?
|
| Actins | 3 | 2023 | 2049 | 0.070 |
Why?
|
| Methods | 2 | 1998 | 1074 | 0.070 |
Why?
|
| Focus Groups | 1 | 2023 | 1382 | 0.070 |
Why?
|
| Thromboembolism | 1 | 2014 | 995 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 11083 | 0.070 |
Why?
|
| Circadian Rhythm | 1 | 1999 | 2567 | 0.070 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 551 | 0.070 |
Why?
|
| Delivery, Obstetric | 1 | 2014 | 931 | 0.070 |
Why?
|
| Genes, Developmental | 1 | 2007 | 38 | 0.070 |
Why?
|
| Quality of Life | 3 | 2022 | 13265 | 0.070 |
Why?
|
| Receptor, EphA2 | 1 | 2006 | 41 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 358 | 0.070 |
Why?
|
| Patient Readmission | 3 | 2015 | 3241 | 0.070 |
Why?
|
| Mass Spectrometry | 2 | 2021 | 2189 | 0.070 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2008 | 282 | 0.070 |
Why?
|
| Accidental Falls | 1 | 2014 | 1056 | 0.070 |
Why?
|
| DNA Repair Enzymes | 1 | 2008 | 344 | 0.070 |
Why?
|
| Rats, Wistar | 2 | 2007 | 1844 | 0.070 |
Why?
|
| Nuclear Proteins | 3 | 2011 | 5786 | 0.070 |
Why?
|
| Inpatients | 1 | 2018 | 2536 | 0.070 |
Why?
|
| Medicare | 2 | 2022 | 6717 | 0.070 |
Why?
|
| Myoblasts, Skeletal | 1 | 2006 | 73 | 0.070 |
Why?
|
| DNA Repair | 3 | 2017 | 2038 | 0.070 |
Why?
|
| Bupropion | 2 | 2021 | 304 | 0.070 |
Why?
|
| Nigeria | 1 | 2009 | 762 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 1734 | 0.070 |
Why?
|
| Vesicular Transport Proteins | 1 | 2009 | 374 | 0.070 |
Why?
|
| Goals | 1 | 2011 | 707 | 0.070 |
Why?
|
| Fibrinolysin | 1 | 2006 | 131 | 0.070 |
Why?
|
| Government Programs | 1 | 2018 | 279 | 0.070 |
Why?
|
| Plasminogen | 1 | 2006 | 146 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 1664 | 0.070 |
Why?
|
| Mutant Proteins | 2 | 2022 | 491 | 0.070 |
Why?
|
| Pediatrics | 3 | 2000 | 3586 | 0.070 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2006 | 540 | 0.070 |
Why?
|
| Phylogeny | 3 | 2008 | 2774 | 0.070 |
Why?
|
| Animals, Congenic | 1 | 2005 | 27 | 0.070 |
Why?
|
| Rats, Inbred Dahl | 1 | 2005 | 34 | 0.070 |
Why?
|
| Paraffin Embedding | 1 | 2007 | 302 | 0.060 |
Why?
|
| Abnormalities, Multiple | 2 | 2018 | 1414 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2017 | 2976 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 3153 | 0.060 |
Why?
|
| Proteins | 3 | 2021 | 6026 | 0.060 |
Why?
|
| Radiology | 1 | 2019 | 2101 | 0.060 |
Why?
|
| Cesarean Section | 1 | 2014 | 1383 | 0.060 |
Why?
|
| Ethics Committees, Research | 1 | 2007 | 196 | 0.060 |
Why?
|
| Speech Disorders | 1 | 2016 | 180 | 0.060 |
Why?
|
| Hepatocytes | 2 | 2009 | 1230 | 0.060 |
Why?
|
| Rats, Inbred BN | 1 | 2005 | 231 | 0.060 |
Why?
|
| Regional Medical Programs | 1 | 2006 | 66 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2007 | 361 | 0.060 |
Why?
|
| Gene Knockout Techniques | 1 | 2008 | 802 | 0.060 |
Why?
|
| Point Mutation | 1 | 2011 | 1594 | 0.060 |
Why?
|
| Umbilical Cord | 1 | 2007 | 181 | 0.060 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 58559 | 0.060 |
Why?
|
| Massachusetts | 4 | 2014 | 8815 | 0.060 |
Why?
|
| Financing, Government | 1 | 2009 | 472 | 0.060 |
Why?
|
| Cell Line, Tumor | 9 | 2018 | 16891 | 0.060 |
Why?
|
| Kidney | 1 | 2021 | 7013 | 0.060 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2006 | 113 | 0.060 |
Why?
|
| Anemia, Diamond-Blackfan | 1 | 2006 | 136 | 0.060 |
Why?
|
| Queensland | 1 | 2015 | 52 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 2743 | 0.060 |
Why?
|
| Muscular Dystrophies | 1 | 2007 | 389 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 1184 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 1546 | 0.060 |
Why?
|
| Haplotypes | 2 | 2019 | 2764 | 0.060 |
Why?
|
| Xenopus laevis | 1 | 2019 | 965 | 0.060 |
Why?
|
| Lactones | 1 | 2007 | 317 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2024 | 459 | 0.060 |
Why?
|
| Narration | 1 | 2007 | 219 | 0.060 |
Why?
|
| Heart Defects, Congenital | 2 | 2019 | 4673 | 0.060 |
Why?
|
| Pyridines | 1 | 2017 | 2864 | 0.060 |
Why?
|
| Sulfones | 1 | 2007 | 446 | 0.060 |
Why?
|
| Multimedia | 1 | 2005 | 74 | 0.060 |
Why?
|
| Lung Diseases | 1 | 2015 | 1908 | 0.060 |
Why?
|
| Caspases | 1 | 2008 | 876 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2016 | 1826 | 0.060 |
Why?
|
| Zinc Fingers | 1 | 2016 | 568 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 3608 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 621 | 0.060 |
Why?
|
| Mitochondria, Muscle | 1 | 2005 | 172 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2010 | 989 | 0.060 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2020 | 993 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2019 | 2497 | 0.060 |
Why?
|
| Energy Metabolism | 3 | 2019 | 2868 | 0.060 |
Why?
|
| Dystrophin | 1 | 2005 | 284 | 0.060 |
Why?
|
| Artifacts | 4 | 2001 | 1894 | 0.060 |
Why?
|
| Proteomics | 1 | 2018 | 3816 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 4221 | 0.060 |
Why?
|
| Calcium-Binding Proteins | 1 | 2009 | 1066 | 0.060 |
Why?
|
| Oocytes | 1 | 2019 | 1165 | 0.060 |
Why?
|
| Obesity | 4 | 2023 | 12869 | 0.060 |
Why?
|
| Crosses, Genetic | 1 | 2005 | 751 | 0.060 |
Why?
|
| Causality | 2 | 2024 | 1241 | 0.060 |
Why?
|
| Mortality | 1 | 2015 | 2881 | 0.060 |
Why?
|
| Fetal Development | 1 | 2009 | 766 | 0.060 |
Why?
|
| Gene Dosage | 1 | 2008 | 1218 | 0.060 |
Why?
|
| Diagnosis | 1 | 2005 | 156 | 0.060 |
Why?
|
| Ribosomal Proteins | 1 | 2006 | 363 | 0.060 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group C | 1 | 2023 | 15 | 0.060 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2017 | 285 | 0.060 |
Why?
|
| Cryopreservation | 1 | 2009 | 717 | 0.060 |
Why?
|
| RNA, Complementary | 1 | 2003 | 45 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 2 | 2023 | 1600 | 0.060 |
Why?
|
| Gene Order | 1 | 2004 | 169 | 0.060 |
Why?
|
| Myocardium | 3 | 2006 | 4690 | 0.060 |
Why?
|
| RNA Probes | 1 | 2003 | 111 | 0.060 |
Why?
|
| Statistical Distributions | 1 | 2003 | 63 | 0.060 |
Why?
|
| Maternal Exposure | 1 | 2010 | 1045 | 0.060 |
Why?
|
| Drug Monitoring | 1 | 2009 | 960 | 0.060 |
Why?
|
| Inflammation | 2 | 2022 | 10718 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2021 | 2666 | 0.050 |
Why?
|
| Emotions | 1 | 2015 | 2733 | 0.050 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2023 | 69 | 0.050 |
Why?
|
| Telepathology | 1 | 2004 | 77 | 0.050 |
Why?
|
| Myositis | 2 | 2005 | 269 | 0.050 |
Why?
|
| Motivation | 1 | 2023 | 1996 | 0.050 |
Why?
|
| Serine C-Palmitoyltransferase | 1 | 2023 | 42 | 0.050 |
Why?
|
| Pathology, Clinical | 1 | 2007 | 375 | 0.050 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2009 | 803 | 0.050 |
Why?
|
| Registries | 3 | 2021 | 8164 | 0.050 |
Why?
|
| Mood Disorders | 1 | 2019 | 1124 | 0.050 |
Why?
|
| Diseases in Twins | 1 | 2015 | 447 | 0.050 |
Why?
|
| Office Visits | 1 | 2007 | 594 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2008 | 5031 | 0.050 |
Why?
|
| Alternative Splicing | 2 | 2023 | 1091 | 0.050 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 2023 | 202 | 0.050 |
Why?
|
| Histones | 1 | 2023 | 2577 | 0.050 |
Why?
|
| Patient Participation | 2 | 2010 | 1435 | 0.050 |
Why?
|
| Myoblasts | 1 | 2003 | 232 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 2269 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3077 | 0.050 |
Why?
|
| Ribonucleases | 1 | 2023 | 276 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 5481 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2007 | 703 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3197 | 0.050 |
Why?
|
| Intellectual Property | 1 | 2022 | 31 | 0.050 |
Why?
|
| Bronchi | 1 | 2006 | 849 | 0.050 |
Why?
|
| Glycolysis | 2 | 2003 | 826 | 0.050 |
Why?
|
| Fertilization | 1 | 1983 | 197 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 3595 | 0.050 |
Why?
|
| Mandatory Testing | 1 | 2002 | 23 | 0.050 |
Why?
|
| Pilot Projects | 4 | 2017 | 8551 | 0.050 |
Why?
|
| Biological Factors | 1 | 2023 | 157 | 0.050 |
Why?
|
| Protein Interaction Mapping | 1 | 2006 | 617 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 9163 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 1765 | 0.050 |
Why?
|
| Homeostasis | 3 | 2011 | 3302 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2008 | 3432 | 0.050 |
Why?
|
| Heart Diseases | 1 | 2015 | 2780 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2013 | 2155 | 0.050 |
Why?
|
| Leiomyoma | 1 | 2006 | 631 | 0.050 |
Why?
|
| Disease | 1 | 2007 | 671 | 0.050 |
Why?
|
| Third-Party Consent | 1 | 2002 | 66 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIbeta Subunit | 1 | 2021 | 2 | 0.050 |
Why?
|
| Binding Sites | 5 | 2011 | 6036 | 0.050 |
Why?
|
| Sphingolipids | 1 | 2023 | 173 | 0.050 |
Why?
|
| Antitubercular Agents | 2 | 2021 | 1373 | 0.050 |
Why?
|
| Sulfurtransferases | 1 | 2021 | 17 | 0.050 |
Why?
|
| Survival | 1 | 2002 | 160 | 0.050 |
Why?
|
| Dehydration | 1 | 2003 | 216 | 0.050 |
Why?
|
| Histidine | 1 | 2022 | 308 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2023 | 412 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2001 | 195 | 0.050 |
Why?
|
| Aldosterone | 1 | 2006 | 866 | 0.050 |
Why?
|
| Physical Education and Training | 1 | 2021 | 100 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2022 | 422 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 1404 | 0.050 |
Why?
|
| Dextroamphetamine | 1 | 2021 | 134 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2003 | 495 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2006 | 1173 | 0.050 |
Why?
|
| Diffusion of Innovation | 2 | 2014 | 727 | 0.050 |
Why?
|
| Amphetamines | 1 | 2021 | 143 | 0.050 |
Why?
|
| Pregnancy Tests | 1 | 2000 | 33 | 0.050 |
Why?
|
| Organ Specificity | 3 | 2012 | 1955 | 0.050 |
Why?
|
| Calibration | 1 | 2003 | 813 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2024 | 64242 | 0.050 |
Why?
|
| Socioeconomic Factors | 3 | 2022 | 7799 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 6469 | 0.040 |
Why?
|
| Exodeoxyribonucleases | 1 | 2001 | 192 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2013 | 4426 | 0.040 |
Why?
|
| Melanoma | 1 | 2019 | 5690 | 0.040 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2004 | 686 | 0.040 |
Why?
|
| Mass Vaccination | 1 | 2021 | 109 | 0.040 |
Why?
|
| Automation | 2 | 2019 | 581 | 0.040 |
Why?
|
| Culture Media | 1 | 2002 | 899 | 0.040 |
Why?
|
| Tremor | 1 | 2021 | 191 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 36271 | 0.040 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2002 | 498 | 0.040 |
Why?
|
| Hereditary Central Nervous System Demyelinating Diseases | 1 | 2020 | 42 | 0.040 |
Why?
|
| Gene Knock-In Techniques | 2 | 2011 | 419 | 0.040 |
Why?
|
| Interinstitutional Relations | 2 | 2003 | 236 | 0.040 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2005 | 565 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 13603 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2015 | 4456 | 0.040 |
Why?
|
| Acid Ceramidase | 1 | 2019 | 21 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 6069 | 0.040 |
Why?
|
| Markov Chains | 3 | 2011 | 965 | 0.040 |
Why?
|
| Environment | 1 | 2006 | 1118 | 0.040 |
Why?
|
| Life Change Events | 1 | 2015 | 953 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2013 | 6363 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 5799 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2016 | 1332 | 0.040 |
Why?
|
| Age Factors | 3 | 2019 | 18328 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2004 | 1996 | 0.040 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2020 | 116 | 0.040 |
Why?
|
| Guidelines as Topic | 2 | 2012 | 1384 | 0.040 |
Why?
|
| Practice Management, Medical | 1 | 2001 | 191 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2019 | 5854 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2009 | 5864 | 0.040 |
Why?
|
| Genetic Techniques | 1 | 2002 | 427 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 2859 | 0.040 |
Why?
|
| Psychiatry | 1 | 2011 | 1690 | 0.040 |
Why?
|
| Survival of Motor Neuron 1 Protein | 1 | 2019 | 64 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2002 | 788 | 0.040 |
Why?
|
| Herpes Zoster | 1 | 2021 | 252 | 0.040 |
Why?
|
| Program Evaluation | 2 | 2013 | 2490 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2024 | 1553 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2006 | 2106 | 0.040 |
Why?
|
| Genome, Fungal | 1 | 2000 | 203 | 0.040 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 1999 | 102 | 0.040 |
Why?
|
| Intensive Care, Neonatal | 1 | 2000 | 197 | 0.040 |
Why?
|
| Jaundice, Neonatal | 1 | 1999 | 71 | 0.040 |
Why?
|
| Micrognathism | 1 | 2018 | 63 | 0.040 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 3204 | 0.040 |
Why?
|
| Psychopharmacology | 1 | 2000 | 148 | 0.040 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 1 | 2019 | 85 | 0.040 |
Why?
|
| Reminder Systems | 1 | 2002 | 387 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2013 | 4214 | 0.040 |
Why?
|
| Selection, Genetic | 1 | 1983 | 868 | 0.040 |
Why?
|
| Telephone | 1 | 2002 | 625 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2014 | 4776 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2007 | 6231 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2004 | 1151 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 3231 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 2800 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2023 | 527 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2013 | 6187 | 0.040 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2019 | 174 | 0.040 |
Why?
|
| Private Sector | 1 | 2021 | 396 | 0.040 |
Why?
|
| Lead Poisoning | 1 | 2000 | 321 | 0.040 |
Why?
|
| Computer User Training | 1 | 1997 | 19 | 0.040 |
Why?
|
| Uterine Neoplasms | 1 | 2006 | 1413 | 0.040 |
Why?
|
| Cities | 1 | 2020 | 541 | 0.040 |
Why?
|
| Hand Deformities, Congenital | 1 | 2018 | 174 | 0.040 |
Why?
|
| Erythrocytes | 2 | 2018 | 2413 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2019 | 388 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2007 | 1972 | 0.040 |
Why?
|
| Microcomputers | 2 | 1995 | 141 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 15394 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2021 | 664 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2009 | 1915 | 0.040 |
Why?
|
| Mammals | 1 | 2023 | 1132 | 0.040 |
Why?
|
| Disease Progression | 4 | 2019 | 13464 | 0.040 |
Why?
|
| Fungal Proteins | 1 | 2001 | 911 | 0.040 |
Why?
|
| Prediabetic State | 1 | 2003 | 547 | 0.040 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2001 | 1489 | 0.040 |
Why?
|
| Drug Interactions | 2 | 2012 | 1415 | 0.040 |
Why?
|
| Galactosyltransferases | 1 | 2018 | 276 | 0.040 |
Why?
|
| India | 1 | 2004 | 2328 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2006 | 3665 | 0.040 |
Why?
|
| Chlamydia Infections | 1 | 2000 | 365 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2004 | 2414 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2007 | 1994 | 0.040 |
Why?
|
| Lithium | 1 | 2020 | 596 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 1826 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2011 | 6349 | 0.030 |
Why?
|
| Denmark | 1 | 2019 | 759 | 0.030 |
Why?
|
| Trans-Activators | 2 | 2003 | 2859 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2017 | 346 | 0.030 |
Why?
|
| Acanthosis Nigricans | 1 | 1996 | 47 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 4352 | 0.030 |
Why?
|
| Potassium Channels | 1 | 2019 | 534 | 0.030 |
Why?
|
| Major Histocompatibility Complex | 1 | 2019 | 928 | 0.030 |
Why?
|
| Gene Library | 2 | 2012 | 1059 | 0.030 |
Why?
|
| Exons | 2 | 2015 | 2392 | 0.030 |
Why?
|
| Muscular Atrophy | 1 | 2019 | 327 | 0.030 |
Why?
|
| Hirsutism | 1 | 1996 | 68 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2019 | 413 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2019 | 454 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2020 | 922 | 0.030 |
Why?
|
| Leukemia | 2 | 2002 | 1521 | 0.030 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 1745 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 2021 | 939 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 6363 | 0.030 |
Why?
|
| Health Planning Councils | 1 | 2015 | 11 | 0.030 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2020 | 496 | 0.030 |
Why?
|
| Hospitals | 2 | 2021 | 3861 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 2004 | 2187 | 0.030 |
Why?
|
| California | 1 | 2019 | 1418 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2002 | 842 | 0.030 |
Why?
|
| Blood Gas Analysis | 1 | 1996 | 377 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 3415 | 0.030 |
Why?
|
| Influenza, Human | 1 | 2006 | 1516 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1999 | 1146 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2022 | 1054 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2020 | 799 | 0.030 |
Why?
|
| Fetal Blood | 2 | 2019 | 1342 | 0.030 |
Why?
|
| HeLa Cells | 2 | 2011 | 3095 | 0.030 |
Why?
|
| Language | 1 | 2024 | 1529 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2000 | 1667 | 0.030 |
Why?
|
| Health Care Costs | 2 | 2018 | 3234 | 0.030 |
Why?
|
| Appendicitis | 1 | 2021 | 674 | 0.030 |
Why?
|
| Chromosome Disorders | 1 | 2017 | 499 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2019 | 753 | 0.030 |
Why?
|
| Nortriptyline | 1 | 2014 | 79 | 0.030 |
Why?
|
| RNA Splicing | 1 | 2019 | 913 | 0.030 |
Why?
|
| Canada | 1 | 2020 | 2108 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 1996 | 426 | 0.030 |
Why?
|
| Spine | 1 | 2021 | 1111 | 0.030 |
Why?
|
| Mice, Knockout | 3 | 2019 | 14354 | 0.030 |
Why?
|
| Amitriptyline | 1 | 2014 | 112 | 0.030 |
Why?
|
| Body Mass Index | 3 | 2017 | 12870 | 0.030 |
Why?
|
| Chromatin | 1 | 2006 | 2938 | 0.030 |
Why?
|
| Rectal Fistula | 1 | 2014 | 75 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 584 | 0.030 |
Why?
|
| Social Security | 1 | 1994 | 101 | 0.030 |
Why?
|
| Neck | 1 | 2018 | 731 | 0.030 |
Why?
|
| Alcoholism | 1 | 2015 | 1964 | 0.030 |
Why?
|
| Genome, Bacterial | 1 | 2019 | 770 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 3217 | 0.030 |
Why?
|
| Fuzzy Logic | 1 | 1994 | 57 | 0.030 |
Why?
|
| Triage | 1 | 2021 | 985 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2019 | 1368 | 0.030 |
Why?
|
| National Human Genome Research Institute (U.S.) | 1 | 2013 | 22 | 0.030 |
Why?
|
| Neoplasm Metastasis | 3 | 2012 | 4888 | 0.030 |
Why?
|
| Insurance Claim Reporting | 1 | 2014 | 165 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 1999 | 1256 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2023 | 3680 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 1995 | 711 | 0.030 |
Why?
|
| Patient Admission | 1 | 2021 | 1366 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2007 | 3975 | 0.030 |
Why?
|
| Myopathies, Structural, Congenital | 1 | 2014 | 103 | 0.030 |
Why?
|
| Cell Survival | 3 | 2009 | 5782 | 0.030 |
Why?
|
| Organizations | 1 | 2014 | 171 | 0.030 |
Why?
|
| England | 1 | 2014 | 523 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 11075 | 0.030 |
Why?
|
| Attitude of Health Personnel | 2 | 2019 | 3864 | 0.030 |
Why?
|
| Medical Audit | 1 | 2014 | 452 | 0.030 |
Why?
|
| Heart | 1 | 2006 | 4382 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 1996 | 1628 | 0.030 |
Why?
|
| Pulse | 1 | 1993 | 218 | 0.030 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 1 | 2012 | 42 | 0.030 |
Why?
|
| Respiration | 1 | 1999 | 1654 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2019 | 3102 | 0.030 |
Why?
|
| Kv1.1 Potassium Channel | 1 | 2012 | 30 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2017 | 1387 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2019 | 1944 | 0.030 |
Why?
|
| Thyroiditis | 1 | 2013 | 86 | 0.030 |
Why?
|
| Face | 1 | 2018 | 1017 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 1999 | 833 | 0.030 |
Why?
|
| Program Development | 1 | 2019 | 1296 | 0.030 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2012 | 119 | 0.030 |
Why?
|
| Schools | 1 | 2021 | 1482 | 0.030 |
Why?
|
| Financing, Organized | 1 | 2014 | 204 | 0.030 |
Why?
|
| Blotting, Northern | 2 | 2004 | 1543 | 0.030 |
Why?
|
| Computers | 2 | 2005 | 596 | 0.030 |
Why?
|
| Alzheimer Disease | 2 | 2011 | 8543 | 0.030 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 882 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2007 | 3603 | 0.030 |
Why?
|
| Fornix, Brain | 1 | 2012 | 71 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2019 | 1048 | 0.020 |
Why?
|
| Models, Animal | 1 | 2018 | 2112 | 0.020 |
Why?
|
| Amniotic Fluid | 1 | 1994 | 378 | 0.020 |
Why?
|
| Transglutaminases | 1 | 2013 | 197 | 0.020 |
Why?
|
| Birth Weight | 1 | 2020 | 2096 | 0.020 |
Why?
|
| Cyclin A | 1 | 2011 | 60 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 656 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2013 | 395 | 0.020 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1995 | 399 | 0.020 |
Why?
|
| Inservice Training | 1 | 2014 | 375 | 0.020 |
Why?
|
| Length of Stay | 2 | 2015 | 6384 | 0.020 |
Why?
|
| Citalopram | 1 | 2014 | 402 | 0.020 |
Why?
|
| Computer Storage Devices | 1 | 1991 | 9 | 0.020 |
Why?
|
| Iodide Peroxidase | 1 | 2013 | 294 | 0.020 |
Why?
|
| Spleen | 1 | 2017 | 2296 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 1997 | 1846 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2021 | 1925 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2019 | 1188 | 0.020 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2014 | 505 | 0.020 |
Why?
|
| Sample Size | 1 | 2014 | 838 | 0.020 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2017 | 1988 | 0.020 |
Why?
|
| Receptors, AMPA | 1 | 2012 | 322 | 0.020 |
Why?
|
| Cyclin E | 1 | 2011 | 156 | 0.020 |
Why?
|
| Biostatistics | 1 | 2012 | 164 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2018 | 2426 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2011 | 294 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2015 | 830 | 0.020 |
Why?
|
| Peptides, Cyclic | 1 | 2013 | 392 | 0.020 |
Why?
|
| Certification | 1 | 2014 | 418 | 0.020 |
Why?
|
| Mathematics | 2 | 2001 | 707 | 0.020 |
Why?
|
| Acne Vulgaris | 1 | 1996 | 356 | 0.020 |
Why?
|
| Positive-Pressure Respiration | 1 | 1995 | 636 | 0.020 |
Why?
|
| Mother-Child Relations | 1 | 2014 | 494 | 0.020 |
Why?
|
| Gene Frequency | 2 | 2011 | 3612 | 0.020 |
Why?
|
| Reference Values | 3 | 2006 | 4918 | 0.020 |
Why?
|
| Adenosine Deaminase | 1 | 2012 | 251 | 0.020 |
Why?
|
| Educational Status | 1 | 1998 | 2511 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2012 | 361 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 1870 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2004 | 5913 | 0.020 |
Why?
|
| Nylons | 1 | 2009 | 46 | 0.020 |
Why?
|
| Cell Separation | 2 | 2006 | 1720 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 10135 | 0.020 |
Why?
|
| Cell Death | 1 | 2015 | 1667 | 0.020 |
Why?
|
| Homozygote | 1 | 2014 | 1788 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 989 | 0.020 |
Why?
|
| Breast Neoplasms | 5 | 2012 | 20999 | 0.020 |
Why?
|
| Alpinia | 1 | 2008 | 1 | 0.020 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2014 | 573 | 0.020 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2009 | 142 | 0.020 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 1996 | 1014 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 2904 | 0.020 |
Why?
|
| Recurrence | 1 | 2021 | 8426 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2018 | 2374 | 0.020 |
Why?
|
| Pulmonary Surfactants | 1 | 2009 | 161 | 0.020 |
Why?
|
| Income | 1 | 1998 | 1867 | 0.020 |
Why?
|
| In Situ Hybridization | 2 | 2003 | 1900 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 1894 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2012 | 672 | 0.020 |
Why?
|
| Cell Adhesion | 2 | 2006 | 3090 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 824 | 0.020 |
Why?
|
| Anisotropy | 1 | 2012 | 1278 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2013 | 950 | 0.020 |
Why?
|
| Methotrexate | 1 | 2015 | 1718 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2021 | 3533 | 0.020 |
Why?
|
| Physicians, Primary Care | 1 | 2015 | 623 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 5756 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2009 | 1154 | 0.020 |
Why?
|
| Glycoproteins | 2 | 2006 | 2205 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2012 | 1694 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2014 | 866 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2006 | 17617 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2018 | 2475 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 11065 | 0.020 |
Why?
|
| Brain Stem Neoplasms | 1 | 2009 | 190 | 0.020 |
Why?
|
| Transfection | 1 | 2015 | 5779 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2009 | 514 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 14478 | 0.020 |
Why?
|
| Colectomy | 1 | 2012 | 687 | 0.020 |
Why?
|
| Hemopexin | 1 | 2006 | 32 | 0.020 |
Why?
|
| Protein Stability | 1 | 2008 | 567 | 0.020 |
Why?
|
| RNA, Ribosomal, 18S | 1 | 2006 | 57 | 0.020 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2006 | 75 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 1795 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 2391 | 0.020 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2006 | 97 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2006 | 161 | 0.020 |
Why?
|
| Hypertension | 2 | 2005 | 8502 | 0.020 |
Why?
|
| RNA Interference | 1 | 2015 | 2836 | 0.020 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2012 | 952 | 0.020 |
Why?
|
| Genes, cdc | 1 | 2006 | 115 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2010 | 9519 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2006 | 79 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2010 | 663 | 0.020 |
Why?
|
| Age of Onset | 1 | 2013 | 3296 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 384 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2010 | 2263 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 6293 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2012 | 1518 | 0.020 |
Why?
|
| Mice, Inbred mdx | 1 | 2005 | 88 | 0.020 |
Why?
|
| Synteny | 1 | 2005 | 77 | 0.020 |
Why?
|
| Pain | 1 | 2021 | 5063 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1996 | 4156 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 3754 | 0.020 |
Why?
|
| Gyrus Cinguli | 1 | 2012 | 1115 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2009 | 1094 | 0.020 |
Why?
|
| Bronchoconstriction | 1 | 2006 | 139 | 0.020 |
Why?
|
| Health Behavior | 1 | 2017 | 2615 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2015 | 2612 | 0.020 |
Why?
|
| Caregivers | 1 | 1998 | 2224 | 0.020 |
Why?
|
| Erythroid Precursor Cells | 1 | 2006 | 211 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2017 | 3299 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 1995 | 2167 | 0.020 |
Why?
|
| Maps as Topic | 1 | 2005 | 18 | 0.020 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2007 | 219 | 0.020 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2006 | 325 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2006 | 277 | 0.020 |
Why?
|
| Breast | 2 | 2004 | 1961 | 0.020 |
Why?
|
| Haptoglobins | 1 | 2006 | 167 | 0.020 |
Why?
|
| Fibroblast Growth Factor 9 | 1 | 2004 | 13 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2006 | 1304 | 0.020 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2004 | 42 | 0.020 |
Why?
|
| Receptors, Neuropeptide | 1 | 2005 | 105 | 0.020 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2004 | 62 | 0.020 |
Why?
|
| Receptor, PAR-2 | 1 | 2004 | 33 | 0.020 |
Why?
|
| Gestational Age | 2 | 2009 | 3566 | 0.020 |
Why?
|
| Carcinoid Tumor | 1 | 2006 | 224 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2006 | 401 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 473 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 477 | 0.010 |
Why?
|
| Disease Models, Animal | 3 | 2009 | 18123 | 0.010 |
Why?
|
| Protein Phosphatase 1 | 1 | 2004 | 134 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2006 | 461 | 0.010 |
Why?
|
| Genes, jun | 1 | 2003 | 68 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2004 | 330 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 2006 | 420 | 0.010 |
Why?
|
| Child Development | 1 | 1995 | 2286 | 0.010 |
Why?
|
| Nuclear Respiratory Factors | 1 | 2003 | 18 | 0.010 |
Why?
|
| Myositis, Inclusion Body | 1 | 2005 | 145 | 0.010 |
Why?
|
| Nuclear Respiratory Factor 1 | 1 | 2003 | 21 | 0.010 |
Why?
|
| NF-E2-Related Factor 1 | 1 | 2003 | 21 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 7401 | 0.010 |
Why?
|
| National Health Programs | 1 | 2007 | 439 | 0.010 |
Why?
|
| Genes, fos | 1 | 2003 | 174 | 0.010 |
Why?
|
| Astrocytes | 1 | 2011 | 1337 | 0.010 |
Why?
|
| Interferon-beta | 1 | 2005 | 345 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 1895 | 0.010 |
Why?
|
| Cell Cycle Proteins | 2 | 2005 | 3443 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2019 | 4641 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 12950 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1999 | 8452 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2003 | 530 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2004 | 321 | 0.010 |
Why?
|
| Genes, Regulator | 1 | 2004 | 374 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 632 | 0.010 |
Why?
|
| Critical Care | 1 | 1995 | 2690 | 0.010 |
Why?
|
| Proto-Oncogenes | 1 | 2003 | 320 | 0.010 |
Why?
|
| Laminin | 1 | 2004 | 405 | 0.010 |
Why?
|
| Cell Movement | 1 | 2015 | 5201 | 0.010 |
Why?
|
| Aneuploidy | 1 | 2006 | 551 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2004 | 330 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 10750 | 0.010 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2004 | 342 | 0.010 |
Why?
|
| Oximetry | 2 | 1997 | 460 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 2006 | 986 | 0.010 |
Why?
|
| Iris Plant | 1 | 2002 | 1 | 0.010 |
Why?
|
| Lipid Peroxidation | 1 | 2003 | 271 | 0.010 |
Why?
|
| Mexican Americans | 1 | 2003 | 165 | 0.010 |
Why?
|
| Dermatomyositis | 1 | 2005 | 256 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 2646 | 0.010 |
Why?
|
| Ribosomes | 1 | 2005 | 501 | 0.010 |
Why?
|
| Bone Development | 1 | 2005 | 472 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2003 | 614 | 0.010 |
Why?
|
| Citric Acid Cycle | 1 | 2003 | 230 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 597 | 0.010 |
Why?
|
| Muscle Development | 1 | 2003 | 259 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2004 | 695 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 1245 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2004 | 449 | 0.010 |
Why?
|
| Molecular Probes | 1 | 2003 | 309 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2004 | 582 | 0.010 |
Why?
|
| Tears | 1 | 2003 | 251 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2005 | 920 | 0.010 |
Why?
|
| Meiosis | 1 | 1983 | 328 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2004 | 801 | 0.010 |
Why?
|
| Neurodegenerative Diseases | 1 | 2010 | 1081 | 0.010 |
Why?
|
| Dogs | 1 | 2005 | 3838 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2004 | 923 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2006 | 1156 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2006 | 3593 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 2008 | 1248 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2011 | 2767 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2003 | 1249 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 1125 | 0.010 |
Why?
|
| Survival Rate | 1 | 2014 | 12685 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 2470 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 3984 | 0.010 |
Why?
|
| Fetus | 1 | 2006 | 1860 | 0.010 |
Why?
|
| Troponin T | 1 | 2004 | 761 | 0.010 |
Why?
|
| Cell Count | 1 | 2003 | 1835 | 0.010 |
Why?
|
| Muscles | 1 | 2003 | 1575 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 855 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2003 | 1806 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2003 | 732 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2004 | 2020 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2014 | 4760 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2006 | 2129 | 0.010 |
Why?
|
| Adenocarcinoma | 2 | 2006 | 6325 | 0.010 |
Why?
|
| Hedgehog Proteins | 1 | 2002 | 768 | 0.010 |
Why?
|
| Liability, Legal | 1 | 1998 | 210 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 2825 | 0.010 |
Why?
|
| Physical Examination | 1 | 2003 | 1244 | 0.010 |
Why?
|
| Mental Recall | 1 | 2003 | 1209 | 0.010 |
Why?
|
| Antioxidants | 1 | 2004 | 1665 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 4459 | 0.010 |
Why?
|
| Collagen | 1 | 2004 | 2634 | 0.010 |
Why?
|
| Neuronal Plasticity | 1 | 2004 | 1429 | 0.010 |
Why?
|
| Nurses | 1 | 2005 | 2467 | 0.010 |
Why?
|
| Patient Advocacy | 1 | 1997 | 360 | 0.010 |
Why?
|
| Learning | 1 | 2004 | 1738 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2004 | 3208 | 0.010 |
Why?
|
| Social Responsibility | 1 | 1997 | 386 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2006 | 3005 | 0.010 |
Why?
|
| Regeneration | 1 | 2002 | 1505 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2008 | 9265 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2005 | 3182 | 0.010 |
Why?
|
| Protein Binding | 1 | 2005 | 9312 | 0.010 |
Why?
|
| Insulin | 1 | 2007 | 6578 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 1994 | 405 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2004 | 3887 | 0.010 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1994 | 582 | 0.010 |
Why?
|
| Social Class | 1 | 2000 | 1995 | 0.010 |
Why?
|
| Calcium | 1 | 2004 | 5722 | 0.010 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1994 | 515 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 10172 | 0.000 |
Why?
|
| Patient Satisfaction | 1 | 1995 | 3440 | 0.000 |
Why?
|